Document Detail


Effect of labetalol on indices of myocardial necrosis in patients with suspected acute infarction.
MedLine Citation:
PMID:  3816835     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The role of combined alpha and beta blockade as a means of limiting infarct size has been studied in a randomised controlled trial using labetalol. Only 166 of 630 (26%) consecutive patients admitted to a cardiac care unit with suspected myocardial infarction were deemed suitable for inclusion; most of the remainder had delayed admission to hospital, were over the age limit of 75, or had complications which precluded the use of labetalol. Those on active treatment received a loading dose followed by a slow intravenous infusion over six hours, and oral therapy for the subsequent five days. Doses were adjusted to maintain systolic pressure in the range 100 to 120 mmHg. The control group received only conventional therapy. Labetalol caused lowering of the blood pressure and heart rate during the phase of intravenous treatment, but little effect occurred subsequently because oral dosage was constrained by low systolic pressures. The group that received active treatment had significantly greater release of CKMB enzyme. Little difference was observed in R wave scores or ejection fraction. Only low doses of labetalol can be used for most patients with acute myocardial infarction. Labetalol cannot be recommended as routine treatment for normotensive patients admitted to hospital with suspected infarction.
Authors:
M E Heber; E Rosenthal; N Thomas; V L Haskett; R D Burwood; J Lutkin; R Vincent; D A Chamberlain
Related Documents :
10875215 - Thrombolytic therapy for acute ischemic stroke.
10639265 - Coronary artery patency and survival in clinical trials.
9631265 - Adjunctive therapy after reperfusion therapy in acute myocardial infarction.
2198125 - Anistreplase: a new thrombolytic for the treatment of acute myocardial infarction.
7215395 - Mitral valve replacement in active rheumatic heart disease in a five years old child.
15646895 - Infarct involution and improved function during healing of acute myocardial infarction:...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European heart journal     Volume:  8     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1987 Jan 
Date Detail:
Created Date:  1987-04-13     Completed Date:  1987-04-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  11-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Blood Pressure / drug effects
Coronary Circulation / drug effects
Creatine Kinase / metabolism
Female
Heart Rate / drug effects
Humans
Isoenzymes
Labetalol / administration & dosage*,  pharmacology,  therapeutic use
Male
Middle Aged
Myocardial Infarction / drug therapy*,  enzymology
Stroke Volume / drug effects
Chemical
Reg. No./Substance:
0/Isoenzymes; 36894-69-6/Labetalol; EC 2.7.3.2/Creatine Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early post-infarction angina. Incidence and prognostic relevance.
Next Document:  Positivization of T wave with or without ST segment elevation in patients with unstable angina. Coro...